Positron Files all Financial Reports and Announces the Company is Current with its OTC Reporting & Disclosures
Positron Corp (OTC: POSC) has achieved 'Pink Current' status with OTC Pink Markets, enhancing transparency regarding its financial health. This status eliminates the 'stop or yield' sign for non-filing companies, allowing for improved credibility. President Adel Abdullah expressed gratitude for shareholder support, emphasizing that this accomplishment is vital for increasing shareholder value and concentrating on revenue growth in cardiac PET imaging. The company aims to upgrade to OTCQB as soon as it meets all trading requirements.
- Achieved 'Pink Current' status, enhancing transparency and credibility.
- Removal of filing restrictions allows greater shareholder confidence.
- Focus on increasing shareholder value and market penetration.
- None.
Niagara Falls, NY , Oct. 29, 2021 (GLOBE NEWSWIRE) -- Positron Corp (“Positron” or the “Company”) (OTC: POSC), a nuclear medicine PET imaging company specializing in the field of cardiac Positron Emission Tomography (“PET”) imaging, is pleased to announce today that the Company is now fully reporting and “Current” with the OTC Pink Markets.
This “Pink Current” status provides greater insight and transparency as to the Company’s structure and financial health. Achieving this Current status also removes the “stop or yield” sign associated with non-filing companies with OTC Markets. Positron plans to upgrade to the OTCQB as soon as it can meet all the requirements to trade on this market.
Adel Abdullah, President of Positron stated: "The Company has returned to being a fully reporting publicly traded security. We appreciate the loyalty, patience, and support from our shareholders during this period. Bringing the Company Pink Current has been a key focus for our management team during the course of 2021. This step is expected to increase shareholder value and allow us to continue focusing on driving market penetration and revenue expansion for Positron’s innovative PET product.”
About Positron Corporation
About Positron: Positron Corporation is a nuclear medicine PET imaging company specializing in the field of cardiac Positron Emission Tomography imaging - the gold standard in cardiac diagnostics. Positron’s innovative PET technology, clinical services and practice solutions enables healthcare providers to more accurately diagnose coronary artery disease and improve patient outcomes while practicing cost effective medicine. Positron's PET only system, market position and approach in facilitating the adoption of cardiac PET are substantial advantages to the growth of the market and Positron.
Forward-Looking Statements
This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Positron Corporation, and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
FOR FURTHER INFORMATION, please visit the company’s website at www.positron.com , or contact:
FAQ
What is Positron Corp's current status with OTC Markets?
How does the 'Pink Current' status affect Positron Corp's shareholders?
What are Positron Corp's future plans regarding OTC trading?
Who is the president of Positron Corp?
What is Positron Corp's focus in the healthcare market?
